Celltrion Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Celltrion Pharm makes prescription medicines, including tablets, capsules, and prefilled-syringe biologics, used to treat conditions ranging from liver disease to autoimmune disorders and cancer.
It supplies these products to patients and healthcare providers in South Korea, and its manufacturing facilities hold Korean, US, and European good-manufacturing-practice certifications. Listed on KOSDAQ, South Korea's tech and small-cap board, the company runs three distinct revenue streams: conventional chemical drugs, biologic medicines, and contract process-development services.
Summary is AI-generated and may contain errors · figures from DART filings
Celltrion Pharm holds the exclusive domestic distribution rights for biologic medicines developed by its parent company, Celltrion, and distributes twelve such products in South Korea.
Celltrion Pharm in five facts
What does Celltrion Pharm do?
Celltrion Pharm makes prescription medicines, including tablets, capsules, and prefilled-syringe biologics, used to treat conditions ranging from liver disease to autoimmune disorders and cancer.
Where is Celltrion Pharm listed and in which sector?
Celltrion Pharm (Korean name: 셀트리온제약) trades under KRX code 068760 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Celltrion Pharm?
Its market capitalisation was US$1.3B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Celltrion Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Celltrion Pharm reported revenue of US$404.9M, operating profit of US$42.3M and net income of US$29.2M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 12.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (preliminary) (fair disclosure)
Celltrion Pharm filed provisional (unaudited) separate results for Q2 2026: revenue of US$107M (+16.75% year on year), operating profit of US$13.5M (+24.37% year on year) and net income of US$9.61M (+23.74% year on year).
Earnings · Aug 4 - Operating results (preliminary) (fair disclosure)
Celltrion Pharm filed provisional (unaudited) separate results for Q1 2026: revenue of US$91.5M (+17.42% year on year), operating profit of US$8.93M (+20.16% year on year) and net income of US$6.1M (+20.44% year on year).
Earnings · May 6 - Operating results (preliminary) (fair disclosure)
Celltrion Pharm filed provisional (unaudited) separate results for FY2025: revenue of US$367M, operating profit of US$38.4M and net income of US$26.5M.
Earnings · Feb 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Celltrion Pharm reported separate results for FY2025: revenue of US$367M (+12.3% year on year), operating profit of US$38.4M (+50.7% year on year) and net income of US$26.5M (+76.4% year on year).
Earnings · Feb 5